George Medicines
PrivateLast Round
Grant
Jul 20, 2022
Total Funding Raised
$1.04M
Momentum Score
75 /100
Company Overview
George Medicines is a late-stage biopharmaceutical company that develops and commercializes single-pill combination therapies for cardiometabolic diseases like hypertension.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials
Business Model
B2B2C
Customer Profile
Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
George Medicines Comps
Public and private peers based on sector, stage, and business model.
George Medicines Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jul 20, 2022 | ||||
| VC Round | Mar 10, 2020 |
Key People
Founding team and executive leadership
George Medicines Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| CUREator | Grant |
| Federation Asset Management | VC Round |
| Brandon Capital | VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 23, 2026
GMRx2 approved for hypertension treatment in the US.
- Mar 16, 2026
Arrotex to commercialize GMRx2 in Australia and New Zealand.
George Medicines Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about George Medicines's valuation, stock price, and market status.
